Zeltzer et al evaluated prognostic factors in patients treated for medulloblastoma. These can help identify patients who may require more aggressive management. The authors are from multiple Children's hospitals in the United States.
Patient selection: 1.5 to 21 years of age
Parameters:
(1) age of the patient
(2) M stage from the classification scheme of Chang et al (see previous section)
(3) area of residual tumor on MRI after surgery in square cm
(4) intensity of therapy
Outcome: progression free survival (PFS) at 5 years
Age of the Patient
M Stage
Residual Tumor
Therapy
5 Year PFS
< 3
NA
NA
reduced
< 32%
< 3
NA
NA
normal
32%
>= 3
0
< 1.5 sq cm
NA
78%
>= 3
0
>= 1.5 sq cm
NA
54%
>= 3
1
NA
NA
57%
>= 3
2, 3 or 4
NA
NA
40%
To read more or access our algorithms and calculators, please log in or register.
